Ginkgo Bioworks IPO: Biotech Bringing Stock via $15 Billion SPAC Deal

By Amber Deter A Ginkgo Bioworks IPO is coming to the market by a special purpose acquisition company (SPAC). Soaring Eagle Acquisition (Nasdaq: SRNG) and Ginkgo announced a merger agreement, and investors want to know when they can expect Ginkgo Bioworks stock.
But is Ginkgo Bioworks a good investment opportunity? Here’s what we know…
Ginkgo Bioworks IPO: The Company

A group of MIT scientists founded Ginkgo Bioworks in 2008. It’s a biotech company based in Boston, Massachusetts. The goal is to build made-to-order microbes for customers to grow better products instead of manufacturing them. The company does this with its cell programming platform. The platform uses …read more



Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.